The effect of desolvation on the binding of inhibitors to HIV-1 protease and cyclin-dependent kinases: Causes of resistance

被引:8
|
作者
Fong, Clifford W. [1 ]
机构
[1] Eigenenergy, Adelaide, SA, Australia
关键词
QSAR model; HIV-1 protease inhibitors; CDK inhibitors; Kinase binding; Quantum mechanics; RECOGNITION; ENTHALPY; ENERGY; MODELS;
D O I
10.1016/j.bmcl.2016.05.080
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Studies of the cyclin-dependent kinase inhibitors and HIV-1 protease inhibitors have confirmed that ligand-protein binding is dependent on desolvation effects. It has been found that a four parameter linear model incorporating desolvation energy, lipophilicity, dipole moment and molecular volume of the ligands is a good model to describe the binding between ligands and kinases or proteases. The resistance shown by MDR proteases to the anti-viral drugs is multi-faceted involving varying changes in desolvation, lipophilicity and dipole moment interaction compared to the non-resistant protease. Desolvation has been shown to be the dominant factor influencing the effect of inhibitors against the cyclin-dependent kinases, but lipophilicity and dipole moment are also significant factors. The model can differentiate between the inhibitory activity of CDK2/cycE, CDK1/cycB and CDK4/cycD enzymes. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3705 / 3713
页数:9
相关论文
共 50 条
  • [1] Cyclin-dependent kinases as therapeutic targets for HIV-1 infection
    Rice, Andrew P.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (12) : 1453 - 1461
  • [2] Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes
    Nelson, PJ
    Gelman, IH
    Klotman, PE
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2001, 12 (12): : 2827 - 2831
  • [3] Inhibitors of cyclin-dependent kinases
    Krystof, V
    Strnad, M
    CHEMICKE LISTY, 2001, 95 (05): : 295 - 300
  • [4] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [5] Designing inhibitors of cyclin-dependent kinases
    Hardcastle, IR
    Golding, BT
    Griffin, RJ
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 : 325 - 348
  • [6] Chemical inhibitors of cyclin-dependent kinases
    Meijer, L
    Kim, SH
    CELL CYCLE CONTROL, 1997, 283 : 113 - 128
  • [7] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    Molecular Biotechnology, 2001, 19 : 179 - 188
  • [8] INHIBITORS OF MAMMALIAN G(1) CYCLIN-DEPENDENT KINASES
    SHERR, CJ
    ROBERTS, JM
    GENES & DEVELOPMENT, 1995, 9 (10) : 1149 - 1163
  • [9] Pharmacological inhibitors of cyclin-dependent kinases
    Knockaert, M
    Greengard, P
    Meijer, L
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (09) : 417 - 425
  • [10] Chemical inhibitors of cyclin-dependent kinases
    Coleman, KG
    Lyssikatos, JP
    Yang, BV
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 32, 1997, 32 : 171 - 179